Reviewing Fulgent Genetics (NASDAQ:FLGT) and Bullfrog AI (NASDAQ:BFRG)

Fulgent Genetics (NASDAQ:FLGT) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk.

Volatility and Risk

Fulgent Genetics has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.

Institutional & Insider Ownership

48.1% of Fulgent Genetics shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 33.1% of Fulgent Genetics shares are held by insiders. Comparatively, 25.2% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Fulgent Genetics and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fulgent Genetics	-13.62%	-2.55%	-2.36%
Bullfrog AI	N/A	-218.25%	-177.11%

Analyst Ratings

This is a summary of current ratings and target prices for Fulgent Genetics and Bullfrog AI, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fulgent Genetics	1	1	2	0	2.25
Bullfrog AI	1	0	0	0	1.00

Fulgent Genetics currently has a consensus price target of $32.00, indicating a potential upside of 26.13%. Given Fulgent Genetics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Fulgent Genetics is more favorable than Bullfrog AI.

Earnings & Valuation

This table compares Fulgent Genetics and Bullfrog AI”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fulgent Genetics	$283.47 million	2.77	-$42.71 million	($1.39)	-18.25
Bullfrog AI	$60,000.00	165.83	-$6.99 million	($0.69)	-1.26

Bullfrog AI has lower revenue, but higher earnings than Fulgent Genetics. Fulgent Genetics is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Summary

Fulgent Genetics beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.

About Fulgent Genetics

Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.